Cargando…
Ocular surface disorders associated with the use of dupilumab based on WHO VigiBase
Dupilumab is a dual inhibitor of interleukin-4 and interleukin-13 and is mainly used to treat moderate-to-severe atopic dermatitis. Post-marketing safety data related to dupilumab have been accumulated, and it has been found that ocular surface diseases are closely associated with dupilumab treatmen...
Autores principales: | Park, Sunny, Lee, Jung Hyun, Park, Ji Hyun, Park, So Hyang, Park, Song Yi, Jung, Yong Woo, Choi, Soo An |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8275737/ https://www.ncbi.nlm.nih.gov/pubmed/34253801 http://dx.doi.org/10.1038/s41598-021-93750-3 |
Ejemplares similares
-
Short communication: Comments on hair disorders associated with dupilumab based on VigiBase
por: Park, Sunny, et al.
Publicado: (2022) -
VigiAccess: Promoting public access to VigiBase
por: Shankar, Pathiyil Ravi
Publicado: (2016) -
Investigating Overlap in Signals from EVDAS, FAERS, and VigiBase(®)
por: Vogel, Ulrich, et al.
Publicado: (2020) -
Herb-anticancer drug interactions in real life based on VigiBase, the WHO global database
por: Pochet, Stéphanie, et al.
Publicado: (2022) -
A study of the regional differences in propacetamol-related adverse events using VigiBase data of the World Health Organization
por: Jeong, Han Eol, et al.
Publicado: (2022)